TILDRAKIZUMAB (Ilumetri®)
Clinical Indication
Moderate to severe plaque psoriasis
Date of classification
July 2019
Review date
July 2019
Red
Drugs which should be prescribed only by hospital specialists (clinical review by specialist as appropriate and annually as a minimum).